3Vote!
Medical News Today (Free subscription) | 11/02/2009
Melanoma / Skin Cancer NewsStudies Show Early Promise Of MannKind's Cancer Immunotherapy Program In Melanoma, Prostate Cancer And Other Solid MalignanciesAlso Included In: ; Article Date: 02 Nov 2009 - 4:00 PST2 (1 votes)Results of two phase 1 studies demonstrate that the novel, investigational vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response...
4Vote!
Business Wire (Free subscription) | 10/29/2009
... for phase 2 studies. The data are being presented at the International Society for Biological Therapy of Cancer 2009 Annual Meeting. MKC1106-MT is an active immunotherapeutic pr
3Vote!
ireland.com (Free subscription) | 10/21/2009
... million gain arose as a result of a $107.7 million net gain on divestment of the Alzheimer’s Immunotherapy Program (AIP) business to a subsidiary of Johnson & Johnson during the quarter, along with an improved operating performance.During the three-month period ended September 30th, operating loss declined by $29.8 million to $1.7 million as against $31.5 million in the third quarter...
3Vote!
Reuters UK (Free subscription) | 09/29/2009
... an 18.4 percent stake in Elan and substantially all of Elan's rights related to an Alzheimer's immunotherapy program.Elan shares fell 21 cents to $7.13 in morning trading in New York.(Reporting by Jonathan Stempel, editing by Gerald E. McCormick)
5Vote!
CEOWORLD Magazine (Free subscription) | 09/28/2009
... Johnson & Johnson and Elan Corporation plc merger- Announce Definitive Agreement for Alzheimer’s Immunotherapy Program Johnson & Johnson plans to Arbitrate Remicade Rights With Schering-Plough Roche Provides WHO Additional 5.65 Million Packs Of Tamiflu (oseltamivir) for swine flu!
